Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. BioMérieux
  6. News
  7. Summary
    BIM   FR0013280286

BIOMÉRIEUX

(BIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

bioMerieux : BioMérieux, Baxter International Receive CE Mark for Acute Kidney Injury Test

10/22/2021 | 01:38am EST


© MT Newswires 2021
All news about BIOMÉRIEUX
12/01BIOMERIEUX : BioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant
PU
11/03EUROPE : European shares end at record high on strong earnings
RE
11/03Qiagen, BioMerieux Reportedly Exploring Merger
MT
11/03Qiagen, bioMérieux in Merger Talks to Create Medical Diagnostics Behemoth
MT
11/03European shares end at record high on strong earnings
RE
10/22BIOMERIEUX : BioMérieux, Baxter International Receive CE Mark for Acute Kidney Injury Test
MT
10/21BAXTER INTERNATIONAL : Secures CE Mark for Test Predicting Persistent Severe Acute Kidney ..
MT
10/21Biom?rieux S.A. Raises Earnings Guidance for the Year 2021
CI
10/21BIOMERIEUX : BioMérieux – Third-Quarter 2021 Business Review
PU
09/21BioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection ..
CI
More news
Analyst Recommendations on BIOMÉRIEUX
More recommendations
Financials
Sales 2021 3 282 M 3 723 M 3 723 M
Net income 2021 524 M 595 M 595 M
Net cash 2021 198 M 224 M 224 M
P/E ratio 2021 27,2x
Yield 2021 0,58%
Capitalization 13 999 M 15 867 M 15 883 M
EV / Sales 2021 4,21x
EV / Sales 2022 4,13x
Nbr of Employees 12 800
Free-Float 35,7%
Chart BIOMÉRIEUX
Duration : Period :
bioMérieux Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMÉRIEUX
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 118,30 €
Average target price 124,29 €
Spread / Average Target 5,06%
EPS Revisions
Managers and Directors
Alexandre Mérieux Chairman & Chief Executive Officer
Guillaume Bouhours EVP-Finance, Purchasing & Information Systems
Alain Mérieux Founding Chairman
François Lacoste Executive Director-Research & Development
Mark Miller Executive Director-Medical Affairs